In an effort to understand if Treg-restricted deletion of Tnfsf10 would impact tumor growth in a model of an active immune response that justifies a strong involvement of Treg-mediated negative feedback, we treated Tnfsf10L/LFoxp3Cre-YFP.B6 mice with anti–PD-1 therapy and found no change in response to the immunotherapy (Fig. 2D). This evidence concerns the gene TNFSF10 and neoplasm.